Zacks: Analysts Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.25 Earnings Per Share

Analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to announce earnings of ($0.25) per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for BioDelivery Sciences International’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.20). BioDelivery Sciences International reported earnings per share of ($0.29) during the same quarter last year, which would suggest a positive year over year growth rate of 13.8%. The business is scheduled to issue its next earnings results on Friday, March 16th.

On average, analysts expect that BioDelivery Sciences International will report full-year earnings of $0.14 per share for the current fiscal year, with EPS estimates ranging from $0.08 to $0.18. For the next financial year, analysts anticipate that the company will report earnings of ($0.73) per share, with EPS estimates ranging from ($0.96) to ($0.60). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for BioDelivery Sciences International.

Several equities research analysts have recently issued reports on BDSI shares. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, November 13th. Seaport Global Securities started coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, November 27th. Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Finally, Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.38.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down $0.23 during mid-day trading on Friday, hitting $2.17. 476,800 shares of the stock traded hands, compared to its average volume of 555,823. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28. BioDelivery Sciences International has a 12 month low of $1.55 and a 12 month high of $3.60. The stock has a market cap of $134.12, a price-to-earnings ratio of -11.41 and a beta of 0.50.

In other news, Director Mark A. Sirgo sold 108,000 shares of BioDelivery Sciences International stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $2.57, for a total transaction of $277,560.00. Following the completion of the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at approximately $4,521,303.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Sirgo sold 162,509 shares of BioDelivery Sciences International stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total transaction of $451,775.02. Following the sale, the director now directly owns 1,759,262 shares of the company’s stock, valued at $4,890,748.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 980,011 shares of company stock valued at $2,666,275. Insiders own 9.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Inc. lifted its holdings in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 13,341 shares during the last quarter. Royce & Associates LP bought a new stake in shares of BioDelivery Sciences International during the 3rd quarter worth $3,814,000. EAM Investors LLC lifted its stake in BioDelivery Sciences International by 62.1% in the third quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after purchasing an additional 299,163 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in BioDelivery Sciences International in the third quarter worth $116,000. Finally, Krilogy Financial LLC lifted its stake in BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 30,000 shares during the last quarter. 44.16% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect BioDelivery Sciences International, Inc. (BDSI) to Post -$0.25 Earnings Per Share” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/22/zacks-analysts-expect-biodelivery-sciences-international-inc-bdsi-to-post-0-25-earnings-per-share.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply